Onward Medical N.V. (ONWD.BR)
EUR 4.74
(-0.21%)
EUR 4.74
(-0.21%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -35.46 Million EUR | -10.72% |
| 2022 | -32.02 Million EUR | -12.25% |
| 2021 | -28.53 Million EUR | -83.94% |
| 2020 | -15.51 Million EUR | -44.0% |
| 2019 | -10.77 Million EUR | -28.16% |
| 2018 | -8.4 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -9.37 Million EUR | -12.38% |
| 2024 Q2 | -9.37 Million EUR | 0.0% |
| 2023 Q1 | -9.39 Million EUR | 48.15% |
| 2023 FY | -35.99 Million EUR | -12.39% |
| 2023 Q4 | -8.34 Million EUR | 0.22% |
| 2023 Q3 | -8.35 Million EUR | 57.58% |
| 2023 Q2 | -19.7 Million EUR | -109.88% |
| 2022 Q1 | -7.55 Million EUR | 19.26% |
| 2022 Q3 | -8.46 Million EUR | 47.33% |
| 2022 Q4 | -18.1 Million EUR | -114.0% |
| 2022 Q2 | -16.06 Million EUR | -112.75% |
| 2022 FY | -32.02 Million EUR | -12.25% |
| 2021 Q1 | -4.91 Million EUR | -11.22% |
| 2021 FY | -28.53 Million EUR | -83.94% |
| 2021 Q4 | -9.35 Million EUR | 0.0% |
| 2021 Q3 | -9.35 Million EUR | -90.41% |
| 2021 Q2 | -4.91 Million EUR | 0.0% |
| 2020 Q2 | -3.34 Million EUR | 0.0% |
| 2020 Q3 | -4.41 Million EUR | -32.23% |
| 2020 Q1 | -3.34 Million EUR | 0.0% |
| 2020 FY | -15.51 Million EUR | -44.0% |
| 2020 Q4 | -4.41 Million EUR | 0.0% |
| 2019 FY | -10.77 Million EUR | -28.16% |
| 2018 FY | -8.4 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.41 Million EUR | -939.361% |
| ABIVAX Société Anonyme | -127.37 Million EUR | 72.159% |
| Adocia SA | -17.62 Million EUR | -101.243% |
| Aelis Farma SA | -6.46 Million EUR | -448.878% |
| Biophytis S.A. | -14.33 Million EUR | -147.422% |
| Advicenne S.A. | -6.45 Million EUR | -449.218% |
| genOway Société anonyme | 2.06 Million EUR | 1817.09% |
| IntegraGen SA | -183.77 Thousand EUR | -19197.491% |
| Medesis Pharma S.A. | -4.22 Million EUR | -738.499% |
| Neovacs S.A. | -6.9 Million EUR | -413.395% |
| NFL Biosciences SA | -4.43 Million EUR | -700.443% |
| Plant Advanced Technologies SA | -778.23 Thousand EUR | -4456.838% |
| Quantum Genomics Société Anonyme | -3.13 Million EUR | -1030.383% |
| Sensorion SA | -22.31 Million EUR | -58.951% |
| Theranexus Société Anonyme | -7.64 Million EUR | -363.952% |
| TME Pharma N.V. | -5.62 Million EUR | -530.565% |
| Valbiotis SA | -7.16 Million EUR | -395.293% |
| TheraVet SA | -2.17 Million EUR | -1530.401% |
| Valerio Therapeutics Société anonyme | -20.28 Million EUR | -74.798% |
| argenx SE | -417.15 Million EUR | 91.499% |
| BioSenic S.A. | -7.04 Million EUR | -403.736% |
| Celyad Oncology SA | -8.45 Million EUR | -319.333% |
| DBV Technologies S.A. | -85.24 Million EUR | 58.399% |
| Galapagos NV | -88.26 Million EUR | 59.821% |
| Genfit S.A. | -26.58 Million EUR | -33.42% |
| GeNeuro SA | -14.35 Million EUR | -147.003% |
| Hyloris Pharmaceuticals SA | -15.99 Million EUR | -121.741% |
| Innate Pharma S.A. | -12.66 Million EUR | -179.919% |
| Inventiva S.A. | -102.7 Million EUR | 65.472% |
| MaaT Pharma SA | -19.94 Million EUR | -77.822% |
| MedinCell S.A. | -20.97 Million EUR | -69.057% |
| Nanobiotix S.A. | -26.77 Million EUR | -32.428% |
| Oryzon Genomics S.A. | -4.54 Million EUR | -679.545% |
| OSE Immunotherapeutics SA | -22.98 Million EUR | -54.281% |
| Oxurion NV | -12.11 Million EUR | -192.841% |
| Pharming Group N.V. | -4.87 Million EUR | -626.769% |
| Poxel S.A. | -28.76 Million EUR | -23.29% |
| GenSight Biologics S.A. | -29.69 Million EUR | -19.42% |
| Transgene SA | -30.01 Million EUR | -18.163% |
| Financière de Tubize SA | -2.14 Million EUR | -1554.078% |
| UCB SA | 604 Million EUR | 105.871% |
| Valneva SE | -82.08 Million EUR | 56.798% |
| Vivoryon Therapeutics N.V. | -28.83 Million EUR | -22.977% |